Artiva Biotherapeutics (NASDAQ:ARTV) Director Buys 6,552 Shares

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 6,552 shares of the company’s stock in a transaction on Monday, July 13th. The shares were purchased at an average cost of $8.94 per share, for a total transaction of $58,574.88. Following the completion of the transaction, the director directly owned 16,817,573 shares of the company’s stock, valued at approximately $150,349,102.62. This represents a 0.04% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, June 26th, Ra Capital Management, L.P. acquired 1,876 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.98 per share, with a total value of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. acquired 31,000 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $8.88 per share, for a total transaction of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. bought 124,893 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.89 per share, for a total transaction of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. bought 15,414 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $8.99 per share, with a total value of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. purchased 391,019 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $8.57 per share, with a total value of $3,351,032.83.
• On Thursday, June 11th, Ra Capital Management, L.P. purchased 548,580 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $7.91 per share, for a total transaction of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. acquired 103 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $7.00 per share, for a total transaction of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. acquired 479,039 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $6.91 per share, with a total value of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. bought 6,510,416 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $11.52 per share, with a total value of $74,999,992.32.

Artiva Biotherapeutics Stock Up 4.7%

Shares of ARTV stock traded up $0.42 during trading on Tuesday, reaching $9.35. 431,462 shares of the company’s stock were exchanged, compared to its average volume of 388,873. Artiva Biotherapeutics, Inc. has a twelve month low of $2.04 and a twelve month high of $14.53. The firm’s fifty day moving average price is $9.03 and its 200-day moving average price is $6.99. The stock has a market capitalization of $231.13 million, a PE ratio of -2.64 and a beta of 2.18.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the stock. Wall Street Zen downgraded shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. Wedbush boosted their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. HC Wainwright upped their target price on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $41.00 target price on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

Institutional Trading of Artiva Biotherapeutics

A number of institutional investors have recently bought and sold shares of the business. Prelude Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the third quarter valued at approximately $41,000. Bank of America Corp DE increased its position in shares of Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after purchasing an additional 11,190 shares during the period. Bridgeway Capital Management LLC bought a new position in shares of Artiva Biotherapeutics in the second quarter worth $53,000. Qube Research & Technologies Ltd bought a new position in Artiva Biotherapeutics in the 2nd quarter valued at about $58,000. Finally, Jane Street Group LLC acquired a new position in shares of Artiva Biotherapeutics in the 2nd quarter valued at approximately $67,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.